Tango Therapeutics (TNGX) Stock Forecast, Price Target & Predictions
TNGX Stock Forecast
Tango Therapeutics stock forecast is as follows: an average price target of $14.67 (represents a 274.23% upside from TNGX’s last price of $3.92) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
TNGX Price Target
The average price target for Tango Therapeutics (TNGX) is $14.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $13.00. This represents a potential 274.23% upside from TNGX's last price of $3.92.
TNGX Analyst Ratings
According to 4 Wall Street analysts, Tango Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TNGX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tango Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | Joseph Catanzaro | Piper Sandler | - | - | 100.67% | 359.18% |
| Aug 08, 2024 | Robert Driscoll | Wedbush | - | - | 49.08% | 231.63% |
| May 28, 2024 | Robert Burns | H.C. Wainwright | - | - | 88.13% | 231.63% |
The latest Tango Therapeutics stock forecast, released on Sep 17, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $18.00, which represents a 100.67% increase from the stock price at the time of the forecast ($8.97), and a 359.18% increase from TNGX last price ($3.92).
Tango Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $18.00 | $14.67 |
| Last Closing Price | $3.92 | $3.92 | $3.92 |
| Upside/Downside | -100.00% | 359.18% | 274.23% |
In the current month, the average price target of Tango Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tango Therapeutics's last price of $3.92. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 10, 2024 | Jefferies | Underperform | Underperform | Hold |
| Sep 10, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jul 17, 2024 | Jefferies | Buy | Initialise | |
| Jul 09, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 09, 2024 | Wedbush | Buy | Buy | Hold |
| May 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Tango Therapeutics's last stock rating was published by H.C. Wainwright on Oct 28, 2024. The company gave TNGX a "Buy" rating, the same as its previous rate.
Tango Therapeutics Financial Forecast
Tango Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $10.73M | $14.60M | $5.77M | $6.41M | $6.92M | $5.77M | $5.76M | $12.10M | $6.79M |
| Avg Forecast | $7.00M | $6.90M | $6.90M | $7.38M | $8.02M | $8.07M | $7.63M | $7.50M | $8.24M | $7.59M | $7.19M | $6.77M | $6.32M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| High Forecast | $10.88M | $10.73M | $10.73M | $8.15M | $15.95M | $8.35M | $7.63M | $7.50M | $11.33M | $11.80M | $11.17M | $10.52M | $9.83M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| Low Forecast | $5.12M | $5.05M | $5.05M | $6.13M | $5.11M | $7.78M | $7.63M | $7.50M | $6.29M | $5.55M | $5.26M | $4.95M | $4.62M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.41% | 2.03% | 0.85% | 1.01% | 1.23% | 1.02% | 0.99% | 1.84% | 1.04% |
Tango Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $8.24M, with a low forecast of $6.29M, and a high forecast of $11.33M. TNGX's average Quarter revenue forecast represents a -23.19% decrease compared to the company's last Quarter revenue of $10.73M (Sep 23).
Tango Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-25.63M | $-23.25M | $-30.29M | $-30.57M | $-29.51M | $-25.20M | $-25.38M | $-34.48M | $-19.53M |
| Avg Forecast | $-6.42M | $-6.33M | $-6.33M | $-6.77M | $-7.36M | $-7.40M | $-7.00M | $-6.89M | $-7.57M | $-6.97M | $-6.60M | $-6.21M | $-5.80M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-18.03M |
| High Forecast | $-4.70M | $-4.63M | $-4.63M | $-5.63M | $-4.69M | $-7.14M | $-7.00M | $-6.89M | $-5.78M | $-5.10M | $-4.83M | $-4.55M | $-4.24M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-14.42M |
| Low Forecast | $-9.99M | $-9.84M | $-9.84M | $-7.48M | $-14.64M | $-7.67M | $-7.00M | $-6.89M | $-10.40M | $-10.83M | $-10.26M | $-9.66M | $-9.02M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-21.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.68% | 3.52% | 4.87% | 5.27% | 5.70% | 4.85% | 4.74% | 5.71% | 1.08% |
undefined analysts predict TNGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tango Therapeutics's previous annual EBITDA (undefined) of $NaN.
Tango Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-22.26M | $-20.71M | $-25.73M | $-29.06M | $-28.18M | $-24.86M | $-25.04M | $-33.57M | $-19.59M |
| Avg Forecast | $-40.15M | $-40.15M | $-39.93M | $-39.50M | $-36.68M | $-39.79M | $-37.44M | $-33.64M | $-29.73M | $-36.57M | $-35.37M | $-38.16M | $-38.52M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-18.08M |
| High Forecast | $-26.15M | $-26.15M | $-26.01M | $-34.71M | $-28.65M | $-25.91M | $-24.38M | $-21.91M | $-26.55M | $-23.82M | $-23.04M | $-24.85M | $-25.09M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-14.47M |
| Low Forecast | $-69.09M | $-69.09M | $-68.72M | $-41.89M | $-41.26M | $-68.48M | $-64.42M | $-57.89M | $-33.98M | $-62.93M | $-60.87M | $-65.67M | $-66.29M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-21.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.61% | 0.59% | 0.67% | 0.75% | 0.82% | 0.73% | 0.85% | 1.17% | 1.08% |
Tango Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TNGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Tango Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $9.21M | $9.17M | $8.01M | $7.89M | $8.10M | $7.23M | $6.81M | $9.29M | $4.43M |
| Avg Forecast | $5.95M | $5.86M | $5.86M | $6.27M | $6.81M | $6.85M | $6.49M | $6.38M | $7.01M | $6.45M | $6.11M | $5.75M | $5.37M | $4.80M | $4.81M | $4.96M | $5.59M | $4.09M |
| High Forecast | $9.25M | $9.12M | $9.12M | $6.92M | $13.56M | $7.10M | $6.49M | $6.38M | $9.63M | $10.03M | $9.50M | $8.94M | $8.35M | $4.80M | $4.81M | $4.96M | $5.59M | $4.91M |
| Low Forecast | $4.35M | $4.29M | $4.29M | $5.21M | $4.34M | $6.61M | $6.49M | $6.38M | $5.35M | $4.72M | $4.47M | $4.21M | $3.93M | $4.80M | $4.81M | $4.96M | $5.59M | $3.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.43% | 1.50% | 1.39% | 1.47% | 1.69% | 1.50% | 1.37% | 1.66% | 1.08% |
Tango Therapeutics's average Quarter SG&A projection for Dec 23 is $7.01M, based on 6 Wall Street analysts, with a range of $5.35M to $9.63M. The forecast indicates a -23.93% fall compared to TNGX last annual SG&A of $9.21M (Sep 23).
Tango Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.23 | $-0.23 | $-0.29 | $-0.33 | $-0.32 | $-0.28 | $-0.29 | $-0.38 | $-0.28 |
| Avg Forecast | $-0.37 | $-0.37 | $-0.37 | $-0.36 | $-0.34 | $-0.37 | $-0.34 | $-0.31 | $-0.27 | $-0.34 | $-0.33 | $-0.35 | $-0.35 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| High Forecast | $-0.24 | $-0.24 | $-0.24 | $-0.32 | $-0.26 | $-0.24 | $-0.22 | $-0.20 | $-0.24 | $-0.22 | $-0.21 | $-0.23 | $-0.23 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| Low Forecast | $-0.64 | $-0.64 | $-0.63 | $-0.39 | $-0.38 | $-0.63 | $-0.59 | $-0.53 | $-0.31 | $-0.58 | $-0.56 | $-0.61 | $-0.61 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.68% | 0.71% | 0.82% | 0.93% | 1.01% | 0.89% | 1.07% | 1.44% | 0.99% |
According to undefined Wall Street analysts, Tango Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TNGX previous annual EPS of $NaN (undefined).
Tango Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | - | - | 4344.44% | Buy |
| RAPT | RAPT Therapeutics | - | - | 2743.52% | Hold |
| STTK | Shattuck Labs | - | - | 1088.12% | Hold |
| PASG | Passage Bio | - | - | 1076.47% | Buy |
| XLO | Xilio Therapeutics | - | - | 686.52% | Buy |
| BDTX | Black Diamond Therapeutics | - | - | 480.71% | Buy |
| RLAY | Relay Therapeutics | - | - | 308.42% | Buy |
| TNGX | Tango Therapeutics | - | - | 274.23% | Buy |
| PLRX | Pliant Therapeutics | - | - | 205.93% | Buy |
| ARVN | Arvinas | - | - | 174.56% | Buy |
| STOK | Stoke Therapeutics | - | - | 167.72% | Buy |
| CGEM | Cullinan Oncology | - | - | 151.20% | Buy |
| MLYS | Mineralys Therapeutics | - | - | 140.19% | Buy |
| FHTX | Foghorn Therapeutics | - | - | 108.29% | Buy |
| TYRA | Tyra Biosciences | - | - | 100.57% | Buy |
| CNTB | Connect Biopharma | - | - | 50.00% | Buy |
| NRIX | Nurix Therapeutics | - | - | 46.03% | Buy |
| EWTX | Edgewise Therapeutics | - | - | 39.75% | Buy |
| THRD | Third Harmonic Bio | - | - | 29.51% | Buy |
| KYMR | Kymera Therapeutics | - | - | 14.50% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | - | - | 6.84% | Buy |